NVCR
NovoCure Ltd.
NASDAQ · Healthcare · Medical - Instruments & Supplies · JE
$16.25
+0.15%Price chart
Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15
Key dataSep 15, 2026
Open$16.03
From 52W high−18.73%
Volume451434.00
Market cap$1.89B
P/E (TTM)—
P/S (TTM)2.7x
Div yield—
Key dataSep 15, 2026
Open
$16.03
From 52W high
−18.73%
Volume
451434.00
Market cap
$1.89B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.5x
P/E (TTM)
—
RSI (14)
47.2
MomentumView details →
1D Return
+0.15%
YTD Return
+27.34%
SummaryUpdated Jun 1, 2026
NovoCure Limited (NASDAQ:NVCR) is a Jersey-incorporated oncology company founded in 2000 that has developed a novel cancer treatment technology called Tumor Treating Fields (TTFields). The company went public in 2015 and has since established itself as a pioneer in delivering electric field therapy for solid tumor cancers. NovoCure operates globally with commercial presence in the United States, Europe, Japan, and other international markets, focusing on bringing its unique non-invasive treatment modality to cancer patients worldwide.
Similar companies
Latest newsMore news →